What does dupilumab loe mean - patent?

LOE in the context of dupilumab patents is most commonly an abbreviation for “Letter of Exclusivity.”

When a new drug is approved, the U.S. Food and Drug Administration (FDA) can issue a Letter of Exclusivity that grants the sponsor exclusive marketing rights for a specific period (typically 12 years for a new molecular entity and an additional 5 years for a new indication). In a patent document, “dupilumab LOE” usually refers to the exclusivity period that the sponsor (e.g., Regeneron/Filag) has been granted for dupilumab and its approved uses. The patent may cite the LOE to:

1. Demonstrate the time‑frame of market protection – The exclusivity period defines when the drug is legally protected from generic entry.
2. Justify claims on specific formulations or uses – The LOE can be used to argue that certain formulations or indications are still under exclusive control.
3. Align patent strategy with regulatory status – Knowing the LOE helps in planning secondary patents, data exclusivity, or market launch timing.

What does the LOE actually mean?

Why the LOE matters for patents

1. Scope of Protection – The LOE defines what the sponsor can legally market. Patents that cover the same therapeutic use may be considered secondary to the LOE, but they can still provide protection for new formulations or delivery methods that are not covered by the exclusivity.
2. Strategic Patenting – Sponsors often file additional patents (e.g., for dosing regimens, formulation, delivery devices) before the LOE expires to extend market control beyond the regulatory exclusivity period.
3. Patent‑Exclusivity Interaction – The exclusivity period and the patent life run in parallel. While the LOE stops generics from entering the market, a patent can prevent other competitors from producing any form of the drug until the patent expires.

Quick reference for dupilumab

• First FDA approval (atopic dermatitis) – LOE granted 12 years of exclusivity starting 2017.
• Additional indications (asthma, chronic spontaneous urticaria, etc.) – Each received a separate 5‑year exclusivity, often overlapping with the NME exclusivity.
• Current status – The primary NME exclusivity is still in effect, but the additional indication exclusivities are expiring in the early‑to‑mid‑2020s, depending on the specific indication. This means that while the base drug remains protected, competitors may start entering the market for some indications once those LOEs lapse (assuming no overlapping patents or data exclusivity remain).

Bottom line

When you see “dupilumab LOE” in a patent, it is almost certainly pointing to the Letter of Exclusivity that the FDA has granted for dupilumab. This exclusivity period is a regulatory shield that runs concurrently with the patent’s protection, and it’s a key factor in determining when generics can legally come onto the market. If you’re looking at the patent’s claims in relation to the LOE, you’re essentially examining how the patent strategy dovetails with the FDA’s market exclusivity timeline.